Literature DB >> 25366044

Diabetes: Risks of strict glycaemic control in diabetic nephropathy.

Martin H de Borst1, Gerjan Navis1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366044     DOI: 10.1038/nrneph.2014.209

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

Review 3.  Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?

Authors:  Shan Shan Chen; Stephen L Seliger; Linda F Fried
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-09       Impact factor: 2.894

4.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

5.  Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Authors:  Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612

6.  Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.

Authors:  Vasilios Papademetriou; Laura Lovato; Michael Doumas; Eric Nylen; Amy Mottl; Robert M Cohen; William B Applegate; Zubin Puntakee; Jean Francois Yale; William C Cushman
Journal:  Kidney Int       Date:  2014-09-17       Impact factor: 10.612

7.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Authors:  Sophia Zoungas; John Chalmers; Bruce Neal; Laurent Billot; Qiang Li; Yoichiro Hirakawa; Hisatomi Arima; Helen Monaghan; Rohina Joshi; Stephen Colagiuri; Mark E Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Liu Lisheng; Giuseppe Mancia; Michel Marre; David R Matthews; Carl E Mogensen; Vlado Perkovic; Neil Poulter; Anthony Rodgers; Bryan Williams; Stephen MacMahon; Anushka Patel; Mark Woodward
Journal:  N Engl J Med       Date:  2014-09-19       Impact factor: 91.245

8.  Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes.

Authors:  Mark A Espeland; Henry A Glick; Alain Bertoni; Frederick L Brancati; George A Bray; Jeanne M Clark; Jeffrey M Curtis; Caitlin Egan; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Helen P Hazuda; James O Hill; Don Hire; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Tina Killean; Abbas E Kitabchi; William C Knowler; Andrea Kriska; Cora E Lewis; Marsha Miller; Maria G Montez; Anne Murillo; David M Nathan; Ebenezer Nyenwe; Jennifer Patricio; Anne L Peters; Xavier Pi-Sunyer; Henry Pownall; J Bruce Redmon; Julia Rushing; Donna H Ryan; Monika Safford; Adam G Tsai; Thomas A Wadden; Rena R Wing; Susan Z Yanovski; Ping Zhang
Journal:  Diabetes Care       Date:  2014-09       Impact factor: 19.112

Review 9.  Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease.

Authors:  Jelmer K Humalda; Gerjan Navis
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

  9 in total
  3 in total

1.  Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).

Authors:  Aaltje Y Adema; Maarten A de Jong; Martin H de Borst; Pieter M Ter Wee; Marc G Vervloet
Journal:  Nephron       Date:  2016-07-22       Impact factor: 2.847

2.  ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.

Authors:  G Michelle Ducasa; Alla Mitrofanova; Shamroop K Mallela; Xiaochen Liu; Judith Molina; Alexis Sloan; Christopher E Pedigo; Mengyuan Ge; Javier Varona Santos; Yanio Hernandez; Jin-Ju Kim; Cyrille Maugeais; Armando J Mendez; Viji Nair; Matthias Kretzler; George W Burke; Robert G Nelson; Yu Ishimoto; Reiko Inagi; Santanu Banerjee; Shaoyi Liu; Hazel H Szeto; Sandra Merscher; Flavia Fontanesi; Alessia Fornoni
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 19.456

Review 3.  Effects of glycaemic management on diabetic kidney disease.

Authors:  Richard J MacIsaac; George Jerums; Elif I Ekinci
Journal:  World J Diabetes       Date:  2017-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.